TriSalus Life Sciences Inc
TLSI
Company Profile
Business description
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Contact
6272 W. 91st Avenue
WestminsterCO80031
USAT: +1 888 321-5212
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
110
Stocks News & Analysis
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,996.90 | 78.80 | -0.87% |
| CAC 40 | 8,216.51 | 5.01 | 0.06% |
| DAX 40 | 24,934.61 | 65.92 | 0.27% |
| Dow JONES (US) | 48,978.20 | 1.02 | 0.00% |
| FTSE 100 | 10,121.40 | 116.83 | 1.17% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,450.14 | 54.32 | 0.23% |
| Nikkei 225 | 52,518.08 | 685.28 | 1.32% |
| NZX 50 Index | 13,663.58 | 76.35 | 0.56% |
| S&P 500 | 6,911.79 | 9.74 | 0.14% |
| S&P/ASX 200 | 8,682.80 | 88.50 | -1.01% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |